This Medudy course is a video tutorial for physicians on the topic of “Darolutamide + ADT for Metastatic Hormone-Sensitive Prostate Cancer (ARASEC).” The format used here is a “Journal Club Summary,” in which we summarize the latest and most clinically relevant studies for you.
For metastatic hormone-sensitive prostate cancer (mHSPC), the combination of an androgen receptor pathway inhibitor (ARPI) and androgen deprivation therapy (ADT) has become established internationally as the guideline-recommended standard of care, to the extent that ADT monotherapy is now rarely used as a control arm in clinical trials, particularly in the United States. To nevertheless generate additional evidence for the combination of darolutamide and ADT specifically in U.S. patients, the ARASEC study was designed in parallel with the global ARANOTE study. ARASEC compares darolutamide + ADT with an external ADT monotherapy comparison arm from the Phase 3 CHAARTED trial, selected using a recognized propensity score matching method.
The course will cover the study’s innovative design, the matching methodology, and the efficacy, safety, and sensitivity analyses of the study, as well as how these findings fit into the current evidence base.
Note: All “speakers” appearing in Medudy videos are AI-based avatars used to enhance the educational value of the videos. The individuals on whom the avatars are based have explicitly consented to their use. All content is based on high-quality scientific sources and is created and reviewed by the Medudy team of doctors.
At the end of this training you will know:
- the clinical background and relevance of the research question under investigation
- Study design and methodology of the publication to answer the research question
- the results and key takeaways of the publication
- the conclusion of the publication and possible limitations
